Essure is a permanent, non-surgical transcervical sterilization procedure for women developed by Conceptus Inc. It was approved for use in the United States on November 4, 2002.[1] Two economic studies, one of which implemented Essure as an in-office procedure, suggest that Essure could be more cost-effective than laparoscopic bilateral tubal ligation.[2]
FRANKFURT, Germany — German drug company Bayer AG says it has agreed to buy California-based Conceptus for around $1.1 billion to expand the kinds of birth control it offers.
Bayer said Monday it would launch a public offer to pay $31.00 per share for all the stock in Conceptus, Inc., which is based in Mountain View.
Conceptus makes Essure, an irreversible birth control method in which small metal and polyester coils are inserted to block a woman’s fallopian tubes. The procedure can be done in 10 minutes in a doctor’s office.
Bayer already markets birth control pills and intrauterine devices. CEO Marijn Dekkers said that the deal represented a “strategic bolt-on acquisition” and that it was an “excellent fit in the United States,
Short URL: http://www.newsnet14.com/?p=123735
